Special Partner, New Enterprise Associations, Inc.’s healthcare investment team and Resident Fellow of the American Enterprise Institute. Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019.
Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017.
Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004. He had been a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004.
Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor at CNBC. Pfizer Director since 2019. Chair of our Regulatory and Compliance Committee and Member of our Science and Technology Committee.
Under the terms of its Charter, the Regulatory and Compliance Committee is primarily responsible for overseeing and reviewing the Company's healthcare law compliance programs and the status of compliance with laws, regulations, and internal procedures applicable to pharmaceutical sales and marketing activities.